Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes
Yonsei med. j
; Yonsei med. j;: 1127-1136, 2013.
Article
en En
| WPRIM
| ID: wpr-198364
Biblioteca responsable:
WPRO
ABSTRACT
PURPOSE: Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. MATERIALS AND METHODS: After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). RESULTS: Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p<0.001), islet fibrosis (p<0.01), and improved glucose tolerance (p<0.05), with no differences from the pair-fed control group. The retroperitoneal adipose tissue mass was lower in the rimonabant group than those of the pair-fed control and rosiglitazone groups (p<0.05). Rimonabant, pair-fed control, and rosiglitazone groups showed decreased insulin resistance and increased adiponectin, with no differences between the rimonabant and pair-fed control groups. CONCLUSION: Rimonabant had a protective effect on islet morphology in vivo even in established diabetes. However, the protective effect was also reproduced by pair-feeding. Thus, the results of this study did not support the significance of islet CB1 receptors in islet protection with rimonabant in established obesity-associated type 2 diabetes.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Piperidinas
/
Pirazoles
/
Resistencia a la Insulina
/
Intolerancia a la Glucosa
/
Ratas Endogámicas OLETF
/
Tiazolidinedionas
/
Receptor Cannabinoide CB1
/
Proliferación Celular
/
Diabetes Mellitus Tipo 2
/
Ingestión de Alimentos
Límite:
Animals
Idioma:
En
Revista:
Yonsei med. j
Año:
2013
Tipo del documento:
Article